This inventor holds 8 USPTO granted patents, plus 1 CIPO patent. Top assignee: Novo Nordisk A/s. Active years: 1999-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Vedb.ae butted.k, DK (1999 - 2000)
- Vedbæk, DK (2001)
- Vedbaek, DK (2009 - 2014)
Company Filing History:
Years Active: 1999-2014
Title: Michi Egel-Mitani: Innovator in Acylated Polypeptide Technologies
Introduction
Michi Egel-Mitani, an accomplished inventor based in Vedbaek, Denmark, holds eight patents in the field of biochemistry and molecular biology. His innovative spirit and contributions to the scientific community have made significant advancements in the production of acylated polypeptides.
Latest Patents
Among his latest inventions is a method for making acylated polypeptides. This cutting-edge technology involves producing polypeptides in transformed host cells by expressing a precursor molecule which is subsequently acylated in an in vitro step. The invention encompasses DNA sequences, vectors, and transformed host cells essential for the claimed method. Notably, Egel-Mitani's work details particular precursors and acylation methods that allow for preferential acylation in certain lysine ε-amino groups, thus enhancing the efficacy of the polypeptides produced.
Career Highlights
Egel-Mitani is currently employed at Novo Nordisk A/S, a leading global healthcare company known for its focus on diabetes care and hormone replacement therapies. His role in the company has facilitated groundbreaking research and development in biopharmaceuticals, contributing to the advancement of therapeutic proteins.
Collaborations
Throughout his career, Michi Egel-Mitani has enjoyed successful collaborations with notable professionals in his field, including Per Balschmidt and Jan Markussen. These partnerships have further enriched his innovative processes and production techniques in the realm of polypeptide development.
Conclusion
Michi Egel-Mitani exemplifies the spirit of innovation in biochemistry with his significant contributions to the understanding and production of acylated polypeptides. His work not only enhances scientific knowledge but also paves the way for the development of new therapeutic options in medicine. With a solid foundation of patents and collaborations, Egel-Mitani continues to be a valuable asset to the Novo Nordisk A/S team and the scientific community at large.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile